Q-omics provides the consensus-scored MIR1250 profile across patient tissues and cancer cell-line models. MIR1250 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MIR1250 is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, MIR1250 RNA expression shows 14,205 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, LUSC, and TGCT as cancer lineages where MIR1250 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1250 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1250 survival associations across molecular data types. MIR1250 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1250 RNA expression–survival associations across cancer types. High MIR1250 expression shows unfavorable associations in UVM, THYM, ACC, LUSC, UCEC and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MIR1250 RNA expression.
This table summarizes MIR1250 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1250. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1250 shows lower tumor expression in LUSC, LUAD and ESCA and higher tumor expression in KIRC. The LUSC box plot shows higher MIR1250 RNA expression in normal versus tumor tissue (log2 FC = −0.323, t-test p < 0.001).
This table shows molecular features associated with MIR1250 in patient tissues and cancer cell lines. In patient samples, MIR1250 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
